FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986018097> ?p ?o ?g. }

• W2986018097 endingPage "2019" @default.
• W2986018097 startingPage "2005" @default.
• W2986018097 abstract "The current work studied the chemopreventive efficacy of orally administered chitosan coated solid-lipid nanoparticle (c-SLN) encapsulated aspirin (ASP), curcumin (CUR) and free sulforaphane (SFN), ACS-cSLN, in the LSL-KrasG12D/+; Pdx-1Cre/+ transgenic mouse model of pancreatic ductal adenocarcinoma (PDAC). In vitro uptake study and intracellular localization of ODA-FITC labeled ASP and CUR c-SLNs were performed in Panc-1 and MIA PaCa-2 cells by fluorescence microscopy. LSL-KrasG12D/+; Pdx-1Cre/+ transgenic mice (n = 30) were randomly divided into 5 groups. Treatment groups were orally gavaged with ACS c-SLNs in three doses: low (2 + 4.5 + 0.16 mg/kg), medium (20 + 45 + 1.6 mg/kg) and high (60 + 135 + 4.8 mg/kg), respectively. After 20 weeks of treatment, mice pancreas were harvested, stained with dye and scored according to various pancreatic intraepithelial neoplasms (PanIN) categories by an independent observer. In vitro, cellular uptake evaluated on Panc-1 and MIA PaCa-2 cells resulted in higher fluorescence intensities, indicating increased cellular uptake of ASP and CUR c-SLNs. For further evidence, the addition of lysoID (red fluorescence) demonstrated location and uptake of ASP and CUR c-SLNs into the lysosome. In vivo, treatment with ACS c-SLN for 20-weeks did not cause obvious adverse effects on growth and no statistically significant differences in body weight were observed between groups. However, the weight (mean ± SEM) of pancreas at the end of the study was higher in blank c-SLN group (223.6 ± 42.2 mg) compared to low (138.0 ± 26.0 mg; not significant [NS]), medium (145.0 ± 9.0 mg; NS), and high (133.8 ± 20.3 mg; NS) ACS c-SLN treated groups, demonstrating the efficacy of ACS c-SLN nanoformulations. The low, medium and high dose of ACS c-SLN combinations exhibited a reduction in tumor incidence (PanIN count) by 16.6% (P < 0.01), 66.8% (P < 0.01), and 83.4% (P < 0.01), respectively. These studies provide further proof for the use of an oral, low dose nanotechnology-based combinatorial regimen for the chemoprevention of PDAC." @default.
• W2986018097 created "2019-11-22" @default.
• W2986018097 creator A5020916102 @default.
• W2986018097 creator A5021530808 @default.
• W2986018097 creator A5022949485 @default.
• W2986018097 creator A5033541777 @default.
• W2986018097 creator A5048238119 @default.
• W2986018097 creator A5052869079 @default.
• W2986018097 creator A5070581864 @default.
• W2986018097 creator A5070716127 @default.
• W2986018097 creator A5085670235 @default.
• W2986018097 date "2018-01-01" @default.
• W2986018097 modified "2023-09-23" @default.
• W2986018097 title "Novel nano-drug combination therapeutic regimen demonstrates significant efficacy in the transgenic mouse model of pancreatic ductal adenocarcinoma." @default.
• W2986018097 cites W13805819 @default.
• W2986018097 cites W1511118087 @default.
• W2986018097 cites W1553373140 @default.
• W2986018097 cites W1787071860 @default.
• W2986018097 cites W1968812902 @default.
• W2986018097 cites W1972733003 @default.
• W2986018097 cites W1979559554 @default.
• W2986018097 cites W1980127341 @default.
• W2986018097 cites W1982497475 @default.
• W2986018097 cites W1982855449 @default.
• W2986018097 cites W1984034236 @default.
• W2986018097 cites W1985289026 @default.
• W2986018097 cites W1992123338 @default.
• W2986018097 cites W1998624966 @default.
• W2986018097 cites W2001436592 @default.
• W2986018097 cites W2008664171 @default.
• W2986018097 cites W2010573152 @default.
• W2986018097 cites W2016390566 @default.
• W2986018097 cites W2016474925 @default.
• W2986018097 cites W2022779163 @default.
• W2986018097 cites W2026860021 @default.
• W2986018097 cites W2039437347 @default.
• W2986018097 cites W2043415570 @default.
• W2986018097 cites W2046845840 @default.
• W2986018097 cites W2054727211 @default.
• W2986018097 cites W2054889449 @default.
• W2986018097 cites W2055446276 @default.
• W2986018097 cites W2060240525 @default.
• W2986018097 cites W2061501822 @default.
• W2986018097 cites W2068702549 @default.
• W2986018097 cites W2082032738 @default.
• W2986018097 cites W2091010508 @default.
• W2986018097 cites W2092502633 @default.
• W2986018097 cites W2095569714 @default.
• W2986018097 cites W2099329725 @default.
• W2986018097 cites W2101995865 @default.
• W2986018097 cites W2105297086 @default.
• W2986018097 cites W2111114352 @default.
• W2986018097 cites W2111348428 @default.
• W2986018097 cites W2112336067 @default.
• W2986018097 cites W2123579964 @default.
• W2986018097 cites W2129411530 @default.
• W2986018097 cites W2132014528 @default.
• W2986018097 cites W2140872369 @default.
• W2986018097 cites W2141287045 @default.
• W2986018097 cites W2143132394 @default.
• W2986018097 cites W2145037550 @default.
• W2986018097 cites W2147883214 @default.
• W2986018097 cites W2149879397 @default.
• W2986018097 cites W2150604710 @default.
• W2986018097 cites W2153211877 @default.
• W2986018097 cites W2157122000 @default.
• W2986018097 cites W2160391606 @default.
• W2986018097 cites W2169060943 @default.
• W2986018097 cites W2169853073 @default.
• W2986018097 cites W2170443020 @default.
• W2986018097 cites W2235523093 @default.
• W2986018097 cites W2271670590 @default.
• W2986018097 cites W2466072418 @default.
• W2986018097 cites W2485537848 @default.
• W2986018097 cites W2508706926 @default.
• W2986018097 cites W2781525129 @default.
• W2986018097 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6220149" @default.
• W2986018097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30416852" @default.
• W2986018097 hasPublicationYear "2018" @default.
• W2986018097 type Work @default.
• W2986018097 sameAs 2986018097 @default.
• W2986018097 citedByCount "6" @default.
• W2986018097 countsByYear W29860180972020 @default.
• W2986018097 countsByYear W29860180972022 @default.
• W2986018097 countsByYear W29860180972023 @default.
• W2986018097 crossrefType "journal-article" @default.
• W2986018097 hasAuthorship W2986018097A5020916102 @default.
• W2986018097 hasAuthorship W2986018097A5021530808 @default.
• W2986018097 hasAuthorship W2986018097A5022949485 @default.
• W2986018097 hasAuthorship W2986018097A5033541777 @default.
• W2986018097 hasAuthorship W2986018097A5048238119 @default.
• W2986018097 hasAuthorship W2986018097A5052869079 @default.
• W2986018097 hasAuthorship W2986018097A5070581864 @default.
• W2986018097 hasAuthorship W2986018097A5070716127 @default.
• W2986018097 hasAuthorship W2986018097A5085670235 @default.
• W2986018097 hasConcept C102230213 @default.
• W2986018097 hasConcept C104317684 @default.
• W2986018097 hasConcept C121608353 @default.

• next